{
    "nctId": "NCT00328120",
    "briefTitle": "Faslodex 500mg Multiple Dose Tolerability Study in BC Patients",
    "officialTitle": "An Open, Multicentre Phase I Clinical Study to Assess the Tolerability of Fulvestrant 500 mg in Postmenopausal Women With Hormone Receptor Positive Advanced or Recurrent Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "The primary objective of this study is to assess the tolerability of 500mg fulvestrant",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of written informed consent\n* Postmenopausal woman who fulfils any one of the following criteria:\n* Histological or cytological confirmation of breast cancer\n* Estrogen receptor positive (ER+) or progesterone receptor positive (PgR+).\n\nExclusion Criteria:\n\n* Having received any one of the following therapy for advanced or recurrent breast cancer\n* 2 or more regimens of hormonal therapy or immunotherapy or 2 or more regimens of chemotherapy, etc",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}